Pricing Log in Create free account

Larimar Therapeutics, Inc. (LRMR) vs MacroGenics, Inc. (MGNX)

Larimar Therapeutics, Inc. and MacroGenics, Inc. are both Biotechnology companies. Larimar Therapeutics, Inc. and MacroGenics, Inc. are of similar size ($214.7M and $206.7M). Larimar Therapeutics, Inc. has the higher net margin (0.00% vs −7.97%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, Larimar Therapeutics, Inc. leads on 6 and MacroGenics, Inc. on 6.

Valuation

Metric LRMR MGNX Biotechnology median
P/E n/m n/m 8.42
P/S n/m 1.17 10.01
P/B 1.62 5.00 2.21
Price to free cash flow n/m n/m 21.01
EV/EBITDA n/m n/m 0.61
EV/Sales n/m 0.26 9.41
Earnings yield (97.99%) (6.53%) (31.85%)
Free cash flow yield (75.51%) (30.58%) (24.58%)

Profitability

Metric LRMR MGNX Biotechnology median
Gross margin 0.00% 78.07% 65.16%
Operating margin 0.00% (18.73%) 0.00%
Net margin 0.00% (7.97%) 0.00%
Free cash flow margin 0.00% (35.80%) 0.00%
Return on equity (138.41%) (32.61%) (56.36%)
Return on assets (108.53%) (4.94%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric LRMR MGNX Biotechnology median
Revenue growth (TTM) — 21.93% 6.02%
EPS growth (last fiscal year) (71.97%) (10.28%) 30.26%
Revenue growth, 5-year CAGR — 7.35% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric LRMR MGNX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 4.70 2.96 4.72
Net debt to EBITDA 0.79 2.82 0.96

Dividend

Metric LRMR MGNX Biotechnology median
Dividend yield — — 0.08%
Payout ratio — — —

Size

Metric LRMR MGNX Biotechnology median
Market cap 206.73m 214.67m 132.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack